Adipo Therapeutics presented a poster at The Obesity Society annual meeting on our latest advancements to develop a novel treatment for obesity. Obesity is a significant public health challenge, with projections painting a stark reality. By 2030, nearly half of U.S. adults will suffer from obesity.
Title of Poster: Browning of Human Adipocytes and Adipose Tissue Explants by Notch Signaling Inhibitor ADPO-002
Presenter: Muhammad Raisul Abedin, PhD, Senior Scientist at Adipo Therapeutics
Key Takeaways
- ADPO-002 NP inhibits Notch signaling and upregulates key browning marker gene (PGC1A) in human adipocytes in vitro
- ADPO-002 drug substance promotes upregulation of browning marker genes (PDRM16 and PGC1A) in human adipose tissue ex vivo
- ADPO-002 drug substance induces UCP1 expression in human adipose tissue ex vivo, demonstrating its potential for clinical translation to increase energy expenditure
